Top Markets
Coin of the day
Allergy Therapeutics plc Allergy Therapeutics plc

Allergy Therapeutics plc

AGY
Rang in Aktien #35053
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and... Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Aktienkurs
$0.07143683
Zuletzt synchronisiert: 2026-08-14
Marktkapitalisierung
$4.52M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-37.27%
Land
GB
Handel Allergy Therapeutics plc (AGY)

Kategorie

EPS für Allergy Therapeutics plc (AGY)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Allergy Therapeutics plc beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Allergy Therapeutics plc von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber